Issue StoriesManufacturing and Industry News
Contracts are already signed with three distributors to market the Nasal Aire interface to the home care markets in the United States and abroad, as well as the domestic hospital market, and the company is in negotiations with numerous other international distribution networks. According to analyst reports, the sleep apnea market is growing at a pace of 25% annually, with 40% of the market devoted to respiratory products, says Patrick Karem, CEO of Innomed Technologies. Furthermore, 150 physicians from across the country serve on Innomeds advisory board. These physicians have endorsed the product and have expressed great enthusiasm in getting this innovative device on the market and to patients in need. (800) 200-9842; www.innomedinc.com. Upcoming Conference For more information, contact Mary Beth Rogers at (724) 935-0836 or visit www.dentalsleepmed.org. Nonin Announces Updated Web Site Respironics and Novametrix Sign $90-Million Merger Agreement Novametrix is an excellent fit strategically and operationally. This is a highly synergistic transaction in terms of technology, products, and markets served, says James W. Liken, president and CEO of Respironics. In addition, our sales and marketing efforts are complementary. We expect the transaction to be accretive in the first full year following the acquisition. Combined revenues of the two companies are approximately $490 million for the latest 12 months. This tax-free, stock-for-stock transaction is valued at $8.65 per share to the Novametrix stockholders, or $90 million, based on the assumption of approximately $6 million in debt and Respironics December 17, 2001, closing price of $34.59. Novametrix board of directors and management team strongly endorse this tax-free transaction and believe it is an excellent opportunity for Novametrix stockholders, says William J. Lacourciere, chairman and CEO of Novametrix. As part of this acquisition, Novametrix becomes an important contributor to Respironics growth in revenues and earnings. This was an important consideration in deciding on a stock-for-stock transaction. For more information on the acquisition, visit www.respironics.com and www.novametrix.com. DeVilbiss and Fisher & Paykel Support ASAA Members of the Industry Roundtable make unrestricted tax-deductible contributions to help the association aid those affected by sleep apnea. For more information on ASAA programs and material, call (202) 293-2650 or visit www.sleepapnea.org. New Practice Builders President Medwave Collaborates with LDS Hospital It is anticipated that the study may be complete enough to present data at the European Respiratory Society meeting in August 2002 and the American College of Chest Physicians meeting in November 2002. (800) 894-7601. |
|
|
|
ADDITIONAL ONLINE RESOURCES |
|